← All trials
NCT04624854
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2020
- Primary completion
- Oct 26, 2023
- Completion date
- Oct 26, 2023
- First posted
- Nov 12, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 8250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harbin Medical UniversityLead sponsor
- Harbin Medical UniversityOverall official - principal investigator
- Harbin Medical UniversityReponsible party - principal investigator
- Lepu Medical Technology (Beijing) Co., Ltd.Collaborator
- Chinese Society of CardiologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.